This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joukhadar, C.
Right arrow Articles by Müller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joukhadar, C.
Right arrow Articles by Müller, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2003, p. 3099-3103, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3099-3103.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans

Christian Joukhadar,1* Heino Stass,2 Ulrike Müller-Zellenberg,1 Edith Lackner,1 Florian Kovar,1 Erich Minar,3 and Markus Müller1

Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics,1 Department of Internal Medicine II, Division of Angiology, University of Vienna Medical School, Vienna, Austria,3 Bayer AG Pharma Research Center, Institute of Clinical Pharmacology, Wuppertal, Germany2

Received 22 January 2003/ Returned for modification 26 April 2003/ Accepted 23 June 2003

The present study addressed the ability of moxifloxacin to penetrate into healthy and inflamed subcutaneous adipose tissues in 12 patients with soft tissue infections (STIs). Penetration of moxifloxacin into the interstitial space fluid of healthy and inflamed subcutaneous adipose tissues was measured by use of in vivo microdialysis following administration of a single intravenous dosage of 400 mg in six diabetic and six nondiabetic patients with STIs. For the entire study population, the mean time-concentration profile of free moxifloxacin in plasma was identical to the time-concentration profile of free moxifloxacin in tissue (P was not significant). For healthy and inflamed adipose tissues for the diabetic subgroup, the mean moxifloxacin areas under the concentration-time curves (AUCs) from 0 to 8 h (AUC0-8s) were 8.1 ± 7.1 and 3.7 ± 1.9 mg·h/liter, respectively (P was not significant). The ratios of the mean AUC0-8 for inflamed tissue/AUC0-8 for free moxifloxacin in plasma were 0.5 ± 0.4 for diabetic patients and 1.2 ± 0.8 for nondiabetic patients (P was not significant). The ratios of the AUCs from 0 to 24 h for free moxifloxacin in plasma/MIC at which 90% of isolates are inhibited were >58 and 121 h for Streptococcus species and methicillin-sensitive Staphylococcus aureus, respectively. Concentrations of moxifloxacin effective against clinically relevant bacterial strains are reached in plasma and in inflamed and healthy adipose tissues. Thus, the pharmacokinetics of moxifloxacin in tissue and plasma support its use for the treatment of STIs in diabetic and nondiabetic patients.

* Corresponding author. Mailing address: Department of Clinical Pharmacology University of Vienna Medical School, Allgemeines Krankenhaus Waehringer, Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-2981. Fax: 43-1-40400-2998. E-mail: christian.joukhadar{at}univie.ac.at.

Antimicrobial Agents and Chemotherapy, October 2003, p. 3099-3103, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3099-3103.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Schintler, M. V., Traunmuller, F., Metzler, J., Kreuzwirt, G., Spendel, S., Mauric, O., Popovic, M., Scharnagl, E., Joukhadar, C. (2009). High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 64: 574-578 [Abstract] [Full Text]  
  • Lipsky, B. A., Giordano, P., Choudhri, S., Song, J. (2007). Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 60: 370-376 [Abstract] [Full Text]  
  • Beer, R., Engelhardt, K. W., Pfausler, B., Broessner, G., Helbok, R., Lackner, P., Brenneis, C., Kaehler, S. T., Georgopoulos, A., Schmutzhard, E. (2007). Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains. Antimicrob. Agents Chemother. 51: 379-382 [Abstract] [Full Text]  
  • Skhirtladze, K., Hutschala, D., Fleck, T., Thalhammer, F., Ehrlich, M., Vukovich, T., Muller, M., Tschernko, E. M. (2006). Impaired Target Site Penetration of Vancomycin in Diabetic Patients following Cardiac Surgery.. Antimicrob. Agents Chemother. 50: 1372-1375 [Abstract] [Full Text]  
  • Ulrich, M., Albers, C., Moller, J.-G., Dalhoff, A., Korfmann, G., Kunkele, F., Doring, G. (2005). Moxifloxacin and Azithromycin but not Amoxicillin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae In Vitro when Administered up to 6 Hours after Challenge. Antimicrob. Agents Chemother. 49: 5119-5122 [Abstract] [Full Text]  
  • Edmiston, C. E. Jr, Krepel, C. J., Kehl, K. S., Seabrook, G. R., Somberg, L. B., Almassi, G. H., Smith, T. L., Loehrl, T. A., Brown, K. R., Lewis, B. D., Towne, J. B. (2005). Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 56: 872-878 [Abstract] [Full Text]  
  • Legat, F. J., Krause, R., Zenahlik, P., Hoffmann, C., Scholz, S., Salmhofer, W., Tscherpel, J., Tscherpel, T., Kerl, H., Dittrich, P. (2005). Penetration of Piperacillin and Tazobactam into Inflamed Soft Tissue of Patients with Diabetic Foot Infection. Antimicrob. Agents Chemother. 49: 4368-4371 [Abstract] [Full Text]  
  • Dehghanyar, P., Burger, C., Zeitlinger, M., Islinger, F., Kovar, F., Muller, M., Kloft, C., Joukhadar, C. (2005). Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses. Antimicrob. Agents Chemother. 49: 2367-2371 [Abstract] [Full Text]  
  • Islinger, F., Bouw, R., Stahl, M., Lackner, E., Zeleny, P., Brunner, M., Muller, M., Eichler, H. G., Joukhadar, C. (2004). Concentrations of Gemifloxacin at the Target Site in Healthy Volunteers after a Single Oral Dose. Antimicrob. Agents Chemother. 48: 4246-4249 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»